The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.
Imiquimod (Zyclara®) has been accepted for restricted use in the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic, visible or palpable actinic keratosis of the full face or balding scalp in immunocompetent adults when other topical treatment options are contraindicated or less appropriate. The restriction limits use to the treatment of large field actinic keratosis (>25cm2).
Pentosan polysulfate sodium (Elmiron®) has been accepted for the treatment of bladder pain syndrome characterised by either glomerulations or Hunner’s lesions in adults with moderate to severe pain, urgency and frequency of micturition. It is noted that this decision takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of pentosan polysulfate sodium. This advice is contingent upon the continuing availability of the PAS in NHSScotland or a list price that is equivalent or lower.
Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.
|« CKS Updates - October 2019||Drug Safety Update - November 2019 »|